Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG5-COOH is a synthesized E3 ligase ligand-linker conjugate that features a Thalidomide-derived cereblon ligand covalently attached to a polyethylene glycol (PEG) linker. This compound facilitates targeted protein degradation through the PROTAC technology by engaging the E3 ubiquitin ligase cereblon. Its primary applications include research in protein homeostasis, cancer therapeutics, and the development of new drug modalities in the field of targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-piperazine-Boc is an E3 ligase ligand-linker conjugate that serves as an intermediate in the synthesis of PROTAC targeting B-cell lymphoma 6 protein (BCL6). This compound plays a significant role in targeted protein degradation, facilitating the selective destruction of BCL6 and aiding in research related to cancer therapeutics. Its application is essential for studies focusing on E3 ligase modulation and PROTAC development in oncology. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Propargyne-PEG2-COOH is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a PEG-based linker suitable for PROTAC applications. This compound features an alkyne moiety, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc). It serves as a valuable tool for research in targeted protein degradation and the development of innovative therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG2-COOH is an E3 ligase ligand-linker conjugate that features the cereblon ligand derived from thalidomide, combined with a PEG-based linker. This compound is designed to enhance targeted protein degradation through PROTAC (Proteolysis Targeting Chimera) technology. It serves as a valuable tool for research in cellular biology and therapeutic applications by enabling precise modulation of protein levels in various biological contexts. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates a cereblon ligand derived from Thalidomide. This compound is designed for use in the synthesis of PROTACs (proteolysis-targeting chimeras), facilitating targeted protein degradation in cellular systems. Its unique structure allows for selective engagement of E3 ligases, providing valuable applications in therapeutic research and drug discovery focused on the modulation of protein levels. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C2-acid is an E3 ligase ligand-linker conjugate that features the Thalidomide-derived cereblon ligand, combined with a suitable linker for applications in PROTAC (Proteolysis Targeting Chimera) technology. This compound facilitates targeted protein degradation, enabling researchers to manipulate protein levels within cells. Its design supports the development of innovative therapeutic strategies by leveraging the ubiquitin-proteasome system for potential applications in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-5-O-CH2-COOH is an E3 ligase ligand-linker conjugate that functions as a selective ligand for the Cereblon (CRBN) protein. Its primary role is to facilitate the recruitment of CRBN, making it a valuable intermediate in the synthesis of PROTAC (Proteolysis Targeting Chimeras) molecules targeting CRBN. This compound is essential for research related to targeted protein degradation and therapeutics aimed at modulating cellular proteins through ubiquitin-proteasome pathways. -
SIRT6 PROTAC Degrader
SZU-B6 is a SIRT6-protein-targeting chimeric degrader that achieves a DC50 of 45 nM and 154 nM in SK-HEP-1 and Huh-7 cell lines, respectively. It effectively inhibits the proliferation of SK-HEP-1 cells with an IC50 of 1.51 μM and suppresses colony formation in both SK-HEP-1 and Huh-7 cells. Additionally, SZU-B6 induces apoptosis and causes a cell cycle arrest in the G2/M phase in SK-HEP-1 cells, demonstrating notable antitumor efficacy in mouse models. This compound serves as a valuable tool for studying the functional roles of SIRT6 in cancer research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate featuring the cereblon ligand derived from Thalidomide. This compound is designed for use in PROTAC (proteolysis targeting chimeras) technology, facilitating the targeted degradation of specific proteins within cellular systems. Its utility in research includes studying protein turnover and exploring therapeutic strategies for various diseases through targeted protein modulation. -
PROTAC Linkers
Biotin-PEG6-Thalidomide serves as a PEG-based PROTAC linker, instrumental in the synthesis of Proteolysis Targeting Chimeras (PROTACs). This compound enhances the delivery and cellular penetration of targeted proteins for ubiquitination and subsequent degradation. Its unique design facilitates the exploration of protein modulation in various biological contexts and therapeutic applications, making it an essential tool for researchers investigating targeted protein degradation processes. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate utilizing the cereblon ligand derived from thalidomide. This compound plays a critical role in the assembly of PROTAC (proteolysis targeting chimera) technologies, facilitating targeted protein degradation. It is primarily used in pharmacological research to investigate E3 ligase-mediated protein modulation and to develop innovative therapeutic strategies in disease treatment. -
Ligands for E3 Ligase
Thalidomide-O-C8-Boc is a derivative of Thalidomide that functions as a ligand for the E3 ubiquitin ligase Cereblon (CRBN). This compound is utilized in the development of PROTACs by facilitating the recruitment of CRBN to target proteins through a linker. Its key biological activity involves modulating protein degradation pathways, making it valuable in drug discovery and therapeutic research targeting diseases linked to aberrant protein expressions. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-C4-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate that incorporates a cereblon ligand derived from Thalidomide. This compound is primarily utilized in the development of PROTACs (proteolysis targeting chimeras), enabling targeted protein degradation. Its unique structure facilitates the recruitment of cognate E3 ligases, thereby promoting the efficient ubiquitination and subsequent degradation of specific target proteins, making it a valuable tool in chemical biology and therapeutic research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG4-COOH is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a PEG4 linker. This compound facilitates the targeted protein degradation through the PROTAC (Proteolysis Targeting Chimera) technology, enhancing the selective modulation of protein levels in cellular environments. It serves as a valuable tool for researchers exploring protein homeostasis, pharmacological modulation, and therapy development in various disease contexts. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG1-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines a thalidomide-based cereblon ligand with a polyethylene glycol (PEG) linker, designed for applications in PROTAC (proteolysis-targeting chimeras) technology. This reagent facilitates the targeted degradation of specified proteins, providing a valuable tool for researchers studying protein homeostasis and therapeutic intervention. Its unique properties make it suitable for various applications in chemical biology, drug discovery, and targeted protein degradation studies. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C3-COOH is an E3 ligase ligand-linker conjugate featuring a Thalidomide-based cereblon ligand. This compound is designed for use in PROTAC (Proteolysis Targeting Chimeras) technology, enabling targeted protein degradation. Its application is critical in studying the modulation of protein levels in various biological contexts, providing valuable insights into cellular pathways and disease mechanisms. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C6-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed to incorporate the cereblon ligand derived from Thalidomide, along with a flexible linker suitable for PROTAC technology. This compound facilitates targeted protein degradation by linking specific binders to E3 ligases, enabling the modulation of protein expression in cellular studies. Its applications extend to research in drug discovery and the development of innovative therapeutic strategies involving targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugates E3
Thalidomide-O-C6-azide is an E3 ligase ligand-linker conjugate that combines the Thalidomide-based cereblon ligand with a versatile linker utilized in PROTAC technology. This compound features an azide functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN groups. Thalidomide-O-C6-azide is valuable for applications in targeted protein degradation and chemical biology studies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C6-NH-Boc is an E3 ligase ligand-linker conjugate featuring a Thalidomide-derived cereblon ligand, designed for use in PROTAC (proteolysis-targeting chimera) applications. This compound serves as a crucial building block for synthesizing MI-389, a potent phthalimide-based degrader derived from the multi-targeted receptor tyrosine kinase inhibitor sunitinib. Thalidomide-NH-C6-NH-Boc enables targeted protein degradation, facilitating research into protein regulation and therapeutic discovery in oncology and other fields. -
SMARCA2 Degrader
A947 is a selective SMARCA2 proteolysis-targeting chimera (PROTAC) that functions as a potent degrader of SMARCA2. It exhibits a binding affinity to the SMARCA2 bromodomain with a Kd value of 93 nM, establishing its effectiveness in mediating targeted protein degradation. This compound has significant applications in cancer research, facilitating studies on the role of SMARCA2 in tumorigenesis and potential therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride functions as an E3 ligase ligand-linker conjugate with high affinity for cereblon (CRBN). This compound is pivotal in the development of Proteolysis Targeting Chimeras (PROTACs), offering a strategic approach to induce targeted protein degradation. Its utility extends to research applications in cellular signaling pathways and therapeutic target validation, enabling the exploration of novel treatment modalities in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-Piperazine-PEG1-NH2 is an E3 ligase ligand-linker conjugate that leverages the Thalidomide-derived cereblon ligand, facilitating targeted protein degradation through the PROTAC technology framework. This compound is designed for use in research applications aimed at elucidating E3 ligase biology and developing innovative therapeutic strategies. Its unique structure promotes effective interactions with cellular proteins, enhancing the specificity and efficiency of targeted degradation approaches. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C6-NH2 TFA is an E3 ligase ligand-linker conjugate that combines the cereblon ligand derived from thalidomide with a hexylamine linker. This compound is designed for use in PROTAC technology, facilitating targeted protein degradation. It demonstrates significant potential in biochemical research, particularly in drug discovery and development focused on modulating protein levels through E3 ligase recruitment. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-PEG2-C2-NH-Boc is an E3 ligase ligand-linker conjugate that features a thalidomide-based cereblon ligand combined with a polyethylene glycol (PEG) linker. This compound is designed for the synthesis of dBRD9, a selective PROTAC degrader that targets BRD9, facilitating investigations into BAF complex biology. It serves as a valuable tool in research applications focused on targeted protein degradation and the modulation of cellular pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate featuring a Thalidomide-based cereblon ligand. This compound is designed for use in PROTAC technology, facilitating targeted protein degradation. Its unique structure allows for the recruitment of E3 ligases, making it valuable in studies related to cellular processes and therapeutic development for various diseases. -
E3 Ligase Ligand-linker Conjugate
Thalidomide-PEG2-C2-NH2 TFA is an E3 ligase ligand-linker conjugate that combines the Thalidomide-derived cereblon ligand with a two-unit polyethylene glycol (PEG) linker. This compound is designed for use in the PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted protein degradation by promoting interactions with E3 ligases. It is applicable in research focused on cellular protein regulation and therapeutic development in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-C3-PEG3-C1-NH2 is an E3 ligase ligand-linker conjugate that combines a thalidomide-based cereblon ligand with a three-unit PEG linker. This compound facilitates targeted protein degradation through PROTAC (Proteolysis Targeting Chimera) technology, enhancing the specificity and efficacy of the therapeutic approach. It is suitable for research applications in the areas of protein modulation and drug discovery. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride is a conjugate that targets E3 ligases, featuring a specific ligand and a flexible linker. This compound exhibits immunomodulatory properties and is utilized in cancer research, aiding investigations into targeted protein degradation and therapeutic strategies. Its unique structure facilitates the study of E3 ligase interactions, making it a valuable tool in oncology and drug development research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-Piperazine-PEG2-NH2 is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a PEG2 linker, facilitating targeted protein degradation through the PROTAC technology. This compound is designed to enhance the specificity and efficacy of protein recruitment to the E3 ligase, making it a valuable tool for investigating the mechanisms of targeted ubiquitination and therapeutic intervention in various diseases. Its applications extend to drug discovery, particularly in the development of innovative treatments for conditions reliant on protein homeostasis. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA is an engineered E3 ligase ligand-linker conjugate that features a Thalidomide-based cereblon ligand combined with a three-unit PEG linker suitable for PROTAC technology. This compound facilitates targeted protein degradation through selective E3 ligase recruitment, making it valuable for studies in cellular biology and therapeutic applications. Its unique structure enhances solubility and stability in biological systems, promoting efficient conjugation in research endeavors. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG3-COOH is an E3 ligase ligand-linker conjugate that features a thalidomide-derived cereblon ligand combined with a PEG3 linker. This compound facilitates the targeted ubiquitination of specific proteins through PROTAC technology, promoting their degradation. It serves as a valuable tool for studies involving protein regulation and the development of targeted protein degradation strategies in cellular and molecular biology research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Propargyne-PEG1-COOH is an E3 ligase ligand-linker conjugate that features a Thalidomide-based cereblon ligand, designed for use in PROTAC (Proteolysis Targeting Chimeras) applications. This compound is a versatile click chemistry reagent, possessing an alkyne moiety that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its unique structure enables targeted protein degradation, making it a valuable tool for research in cellular signaling and therapeutics. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Propargyne-PEG3-COOH is an E3 ligase ligand-linker conjugate featuring a Thalidomide-derived cereblon ligand combined with a PEG3 linker, designed for use in PROTAC technology. This compound functions as a click chemistry reagent, possessing an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its applications in targeted protein degradation research make it a valuable tool for exploring protein regulation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine-PEG3-COOH is an E3 ligase ligand-linker conjugate that combines the thalidomide-derived cereblon ligand with a PEG3 linker. This compound is designed for use in PROTAC (proteolysis-targeting chimera) technology, enabling targeted protein degradation. Its mechanism allows for selective modulation of protein levels, making it valuable in drug discovery and therapeutic research focused on protein homeostasis and regulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride serves as a synthesized E3 ligase ligand-linker conjugate, featuring a cereblon ligand derived from Thalidomide and a three-unit polyethylene glycol (PEG) linker. This compound is essential for the development of proteolysis-targeting chimeras (PROTACs), enabling targeted degradation of specific proteins in cellular research. Its unique structure facilitates effective interactions with E3 ligases, making it a valuable tool for studying protein regulation and potential therapeutic applications in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate, featuring a Thalidomide-based cereblon ligand connected by a PEG3 linker. This compound is designed to facilitate targeted protein degradation via PROTAC (Proteolysis Targeting Chimera) technology. Its biological activity makes it suitable for applications in protein regulation studies and drug discovery research, particularly in exploring E3 ligase-mediated pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C5-acid is a synthesized E3 ligase ligand-linker conjugate designed to engage cereblon, a key target in the ubiquitin-proteasome system. This compound serves as a crucial component in PROTAC technology, facilitating targeted protein degradation. Its utility in research includes the development of novel therapeutic strategies aimed at modulating protein levels in various biological contexts. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate designed to target cereblon. This compound utilizes a Thalidomide-based ligand and incorporates a PEG2 linker, facilitating the development of PROTAC (Proteolysis Targeting Chimera) technology. It is primarily used in chemical biology research to modulate protein levels through targeted degradation, making it valuable for investigations in cancer and other diseases where protein regulation is essential. -
PROTAC Linkers
Thalidomide-O-amido-PEG4-propargyl is a PEG-based PROTAC linker designed for the synthesis of Proteolysis Targeting Chimeras (PROTACs). This compound features an alkyne functional group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) for efficient conjugation with azide-containing molecules. Its unique properties enable precise modulation of target protein degradation, supporting research in targeted protein modulation and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C8-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate featuring the cereblon ligand derived from thalidomide, combined with a C8 linker. This compound is designed for use in PROTAC technology, facilitating the targeted degradation of proteins via the ubiquitin-proteasome pathway. Its application in chemical biology includes studies of protein modulation and therapeutic strategies in oncology and other disease models, enabling researchers to explore novel approaches in targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG5-NH2 hydrochloride is an E3 ligase ligand-linker conjugate featuring the Thalidomide-derived cereblon ligand. This compound is designed to facilitate targeted protein degradation through PROTAC technology, enhancing cellular activity against specific protein targets. Its unique structure supports applications in drug development and research focused on modulating protein levels in various biological systems. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PEG2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that integrates the Thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker, designed for use in PROTAC (Proteolysis Targeting Chimera) technology. This compound facilitates targeted degradation of specific proteins via the ubiquitin-proteasome pathway, making it a valuable tool for research in targeted protein modulation. Its application extends to studies in cancer biology and therapeutic development, where selective protein degradation is crucial. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG3-NH-Boc is an E3 Ligase Ligand-Linker Conjugate that targets Cereblon. This compound facilitates the recruitment of the CRBN protein, playing a critical role in the development of targeted protein degradation strategies. The Boc protecting group can be easily removed under acidic conditions, enabling its use in the synthesis of PROTAC molecules. Thalidomide-NH-PEG3-NH-Boc serves as a key intermediate for CRBN-based PROTAC applications in chemical biology research. -
E3 Ligase Ligand
Thalidomide-5-methyl functions as an E3 ligase ligand, specifically targeting cereblon (CRBN). This compound facilitates the recruitment of CRBN protein, enabling the development of PROTAC (proteolysis-targeting chimeras) for targeted protein degradation strategies. Thalidomide-5-methyl is a valuable tool in chemical biology and drug discovery research, particularly for studies related to targeted therapies and the modulation of protein stability. -
E3 Ligase Ligand-Linker Conjugates Chemical
Thalidomide-4-O-C10-COOH is an E3 ligase ligand-linker conjugate utilized in the synthesis of PROTAC (proteolysis-targeting chimera) compounds. This reagent facilitates targeted protein degradation by promoting the ubiquitination of specific substrates via E3 ligase interaction. It is particularly valuable in drug discovery and development, offering a novel approach for modulating protein levels in various biological systems. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG4-amine is an E3 ligase ligand-linker conjugate designed for use in PROTAC technology. This compound combines the Thalidomide-derived ligand, which targets cereblon, with a PEG4 linker to facilitate the development of bifunctional degraders. Its primary application lies in the degradation of target proteins, enabling novel therapeutic strategies in cancer and other diseases by harnessing the ubiquitin-proteasome system. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-C6-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate that incorporates the Thalidomide-based cereblon ligand within its structure. This compound serves as a crucial building block in the design and synthesis of PROTACs (proteolysis targeting chimeras). Its unique properties facilitate targeted protein degradation, enabling significant advancements in therapeutic research and drug discovery. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C8-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that features a Thalidomide-derived cereblon ligand paired with a C8 linker. This compound is designed for use in PROTAC (Proteolysis Targeting Chimera) applications, facilitating targeted protein degradation through the induction of ubiquitin-proteasome pathway involvement. Its unique structure allows for efficient cellular uptake and modulation of specific protein levels, making it invaluable for research in cellular signaling, disease modeling, and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG4-amine hydrochloride is an E3 ligase ligand-linker conjugate, combining a thalidomide derivative that targets cereblon with a PEG4 linker. This compound is designed for use in Proteolysis Targeting Chimera (PROTAC) technology, facilitating the targeted degradation of specific proteins. Its application extends to various studies in cellular signaling and protein homeostasis, making it a valuable reagent for drug discovery and development in the field of targeted therapies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C4-COOH is an E3 ligase ligand-linker conjugate that combines the cereblon ligand derived from thalidomide with a synthetic linker for targeted protein degradation applications. This compound is designed to facilitate the selective degradation of target proteins through the PROTAC (proteolysis-targeting chimera) mechanism. Its utility spans various biochemical research applications, especially in studies investigating the modulation of intracellular protein levels and the development of therapeutic strategies targeting specific cellular pathways.
